Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

Relypsa Bought Out for $32

Score a win for the Value Stocks group. After covering Relypsa (RLYP) for months, turns out longs concluded correctly a bigger fish would buy this company.

Galenica is buying Relypsa for $32/share.

Galenica wants RLYP's U.S. commercial network. The rights for Veltassa is worth big money, since it is the first time in 50 years a drug for hyperkalemia was approved.Previous: May 27 - Will RLYP Survive?